A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Recruiting

Phase 3

ElafibranorA Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

Sponsor:

Ipsen

Code:

NCT06016842

Conditions

Primary Biliary Cholangitis (PBC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Elafibranor

Matched 80 mg placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Ipsen on 2025-05-28.